Province of South Holland awards a subsidy of €200,000 to a joint project between SeraNovo and PercurosTuesday, January 30, 2018
Over time this will create a new wave of medications in fields including Cancer, HIV and Arthritis. The test of Percuros will be safer and cheaper than commercially available tests, while granting SeraNovo one of the best testing platforms for simulating the human gastro-intestinal tract to optimise their technology and prove its efficacy. Combining these two innovations will allow SeraNovo to bring more cures to patients and come one step closer to solving a big problem the pharmaceutical industry has with declining solubility of newly developed medicines.
ISA Pharmaceuticals’ ISA101 Studied in Phase II Oropharyngeal Cancer Combination Trial at MD Anderson Cancer Center
ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
New England Journal of Medicine Published Open-label Study Showing Brineura® (cerliponase alfa) Reduced the Rate of Clinical Decline of Children with CLN2 Disease, a Form of Batten Disease